BridgeMD
New treatment option for Advanced Solid Tumor
Official title A Study of YL242 in Subjects With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07197827
What this study is testing
What is YL242?
YL242 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for advanced solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged ≥18 years.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Adequate organ and bone marrow function
- Tumor type: Part 1-3: Advanced/unresectable or metastatic solid malignant tumor; Have received at least one prior line of systemic anti-tumor therapy...
You likely can't join if
- Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
- Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases
- Clinically significant concomitant pulmonary disease
- A history of leptomeningeal carcinomatosis or carcinomatous meningitis
- Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol...
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
- Sarasota, Florida, United States
- Boston, Massachusetts, United States
- Grand Rapids, Michigan, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Liverpool, New South Wales, Australia
- Darlinghurst, Victoria, Australia
- Fitzroy, Victoria, Australia
- Heidelberg, Victoria, Australia
- Nedlands, Western Australia, Australia
- Harbin, Heilongjiang, China
- Shanghai, Shanghai Municipality, China
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States; Sarasota, Florida, United States; Boston, Massachusetts, United States; Grand Rapids, Michigan, United States; Nashville, Tennessee, United States; Houston, Texas, United States and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.